Abstract
Background
Methods
Results
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Supplementary Table 2
Supplementary Table 3
Supplementary Table 4
Supplementary Table 5
Supplementary Fig. 1
Fig. 1
Selection of study participants. MetS, metabolic syndrome; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.
![dmj-43-504-g001](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-g001.jpg)
Table 1
Baseline characteristics for both sexes according to development of metabolic syndrome
![dmj-43-504-i001](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-i001.jpg)
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
MetS, metabolic syndrome; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; SUA, serum uric acid.
an=5,188 male, n=2,792 female.
Table 2
Baseline clinical and biochemical characteristic of study subjects based on percent change in serum uric acid levels quartile categories and sex
![dmj-43-504-i002](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-i002.jpg)
Values are presented as mean±standard deviation, number (%), or median (interquartile range). Characteristics of the study population according to the serum uric acid quartile were compared using one-way analysis of variance (ANOVA) or Kruskal-Wallis test for continuous variables and chi-square test for categorical variables.
MetS, metabolic syndrome; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; SUA, serum uric acid.
an=5,188 male, n=2,792 female.
Table 3
Correlations between serum uric acid levels, percent changes in serum uric acid and metabolic parameters according to both sexes
![dmj-43-504-i003](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-i003.jpg)
CRP was log transformed to meet the demands of normal distribution.
BMI, body mass index; eGFR, estimated glomerular filtration rate; BP, blood pressure; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein.
an=5,188 male, n=2,792 female.
Table 4
Hazard ratios and 95% confidence intervals for development of metabolic syndrome according to quartile of percent change in serum uric acid levels: male
![dmj-43-504-i004](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-i004.jpg)
Values are presented as mean±standard deviation, number (%), hazard ratio (95% confidence interval). Model 1: adjusted for age, systolic blood pressure, body mass index, fat-free mass (%), estimated glomerular filtration rate, and smoking status; Model 2: adjusted for Model 1 plus fasting glucose, triglyceride, low density lipoprotein cholesterol, and high density lipoprotein cholesterol; Model 3: adjusted for Model 2 plus baseline SUA; Model 4: adjusted for Model 3 plus fasting insulin.a
UA, serum uric acid; SD, standard deviation; MetS, metabolic syndrome.
an=5,188 male.
Table 5
Hazard ratios and 95% confidence intervals for development of metabolic syndrome according to quartile of percent change in serum uric acid levels: female
![dmj-43-504-i005](/upload/SynapseXML/2004dmj/thumb/dmj-43-504-i005.jpg)
Values are presented as mean±standard deviation, number (%), or hazard ratio (95% confidence interval). Model 1: adjusted for age, systolic blood pressure, body mass index, fat-free mass (%), estimated glomerular filtration rate, and smoking status; Model 2: adjusted for Model 1 plus fasting glucose, triglyceride, low density lipoprotein cholesterol, and high density lipoprotein cholesterol; Model 3: adjusted for Model 2 plus baseline SUA; Model 4: adjusted for Model 3 plus fasting insulin.a
SUA, serum uric acid; SD, standard deviation; MetS, metabolic syndrome.
an=2,792 female.